Abstract
We studied the role of wt-1 as a minimal residual disease (MRD) marker in 46 patients with acute leukemia (AL) (1st CR n = 24; 2nd CR n = 9, in relapse n = 13) after allogeneic bone marrow or peripheral blood stem cell transplantation. Prior to allogeneic transplant, wt-1 transcripts were detected by PCR in 38 of 46 patients (83%) with AL. After transplant, in 14 of 38 patients (37%) wt-1 transcripts were detected in at least one PCR assay at a median of 12 months post transplant (range 1–89 months). Twelve of the 38 patients relapsed after transplant, but only seven of the 12 were wt-1 positive after transplant. In five relapsing patients the wt-1 test remained negative 0 to 3 months prior to relapse. On the other hand, only seven of 14 patients with a positive test for wt-1 after transplant, relapsed consecutively. In 17 of the 46 study patients chromosomal abnormalities had been found prior to transplant (AML-M4eo with inv16 n = 7, AML-M2 with t(8;21) n = 3, AML-M3 with t(15;17) n = 1, AML-M5 with t(4;11) n = 1, ALL with t(9;22) n = 5). In these 17 patients, we analyzed the wt-1 transcript simultaneously with a specific chimeric transcript characteristic for the corresponding chromosomal abnormality. In 32 of 45 samples (71%) the results for the MRD marker and wt-1 transcript were concordant, but differed in 13 patients. We conclude that detection of wt-1 transcripts does not predict leukemic relapse reliably and is therefore not a suitable MRD marker in patients with acute leukemia after allogeneic BM or PBSC transplantation. Bone Marrow Transplantation (2000) 25, 91–96.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus Cell 1990 60: 509–520
Haber Da, Sohn RL, Buckler AL et al. Alternative splicing and genomic structure of the Wilms’ tumor gene wt1 Proc Natl Acad Sci USA 1991 88: 9618–9622
Rauscher FJ III, Morris JF, Tournay OE et al. Binding of the Wilms’ tumor gene locus zinc finger protein to the EGR-1 consensus sequence Science 1990 250: 1259–1262
Madden SL, Cook DM, Morris JF et al. Transcriptional repression mediated by the WT1 Wilms’ tumor gene product Science 1991 253: 1550–1553
Drummond IA, Madden SL, Rohwer P et al. Repression of the insulin-like growth factor gene by the Wilms’ tumor suppressor wt1 Science 1992 257: 674–677
Harrington MA, Konicek B, Song A et al. Inhibition ofcolony-stimulating factor-1 promotor activity by the product of the Wilms’ tumor locus J Biol Chem 1993 268: 21271–21276
Dey BR, Sukhatme VP, Roberts AB et al. Repression of the transforming growth factor-beta 1 gene by the Wilms’ tumor suppressor wt1 gene product Mol Endocinol 1993 8: 591–595
Brieger J, Weidmann E, Fenchel K et al. The expression of the Wilm's tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells Leukemia 1994 8: 2136–2143
Bergmann L, Miething C, Maurer U et al. High levels of Wilms’ tumor gene (wt-1) mRNA in acute myeloid leukmias are associated with a worse long-term outcome Blood 1997 90: 1217–1225
Schmid D, Heinze G, Linnerth B et al. Prognostic significance of wt-1 gene expression at diagnosis in adult de novo acute myeloid leukemia Leukemia 1997 11: 639–643
Beelen DW, Quabeck K, Kaiser B et al. Six weeks of continuous intravenous cyclosporine and short course methotrexate as propyhlaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation Transplantation 1990 50: 421–427
Chomczynski P, Sacchi N . Single step method of RNA isolation by acid guanidium thiocyanate phenol chloroform extraction Anal Biochem 1987 162: 156–159
Inoue K, Sugiyama H, Ogawe H et al. Wt1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia Blood 1994 84: 3071–3079
Elmaagacli AH, Beelen DW, Kroll M et al. Detection of CBFB/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation Bone Marrow Transplant 1998 21: 159–166
Elmaagacli AH, Beelen DW, Kroll M et al. Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation Blood 1997 90: 3230–3231
Repp R, Borkhardt A, Haupt E et al. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis Leukemia 1995 9: 210–216
Ikeda K, Sasaki K, Tasaka T et al. Reverse transcription-polymerase chain reaction for PML-RARα fusion transcripts in acute promyelocytic leukemia and its application to minimal residual leukemia detection Leukemia 1993 7: 544–548
Maurer J, Janssen JWG, Thiel E et al. Detection of chimeric bcr-abl genes in acute lymphoblastic leukaemia by the polymerase chain reaction Lancet 1991 337: 1055–1058
Dveksler GS, Basile AA, Dieffenbach CW . Analysis of gene expression: use of oligonucleotide primers for glyceraldehyde-3-phosphate dehydrogenase. PCR Methods and Applications Cold Spring Harbor Laboratory: Cold Spring Harbor, 1992 1: 283–284
Kwok S, Higuchi R . Avoiding false positives with PCR Nature 1989 339: 237–238
Gluckberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304
Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation New Engl J Med 1975 292: 895–902
Inoue K, Ogawa H, Sonoda Y et al. Aberrant overexpression of the Wilms’ tumor gene (wt-1) in human leukemia Blood 1997 89: 1405–1412
Baird PN, Simmons PJ . Expression of the Wilms’ tumor gene (wt1) in normal hemopoiesis Exp Hematol 1997 25: 312–320
Acknowledgements
This work was supported by a grant from ‘Aktion Kampf dem Krebs’ of the German Cancer Society and a grant from ‘Deutsche Krebshilfe’ No. 70-1669-EL-T. We thank Jitka Stockova and Melanie Kroll for their excellent technical performance of the PCR analyses.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elmaagacli, A., Beelen, D., Trenschel, R. et al. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 25, 91–96 (2000). https://doi.org/10.1038/sj.bmt.1702095
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702095
Keywords
This article is cited by
-
Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism
Journal of Cancer Research and Clinical Oncology (2015)
-
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia
Leukemia (2005)
-
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation
Bone Marrow Transplantation (2004)
-
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
Leukemia (2003)
-
Monitoring Minimal Residual Disease in Leukemia Using Real-time Quantitative Polymerase Chain Reaction for Wilms Tumor Gene (WT1)
International Journal of Hematology (2003)